Cetrelimab
- Generic Name
- Cetrelimab
- Drug Type
- Biotech
- CAS Number
- 2050478-92-5
- Unique Ingredient Identifier
- LYK98WP91F
- Background
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
CD8 PET Imaging in Metastatic Solid Tumours
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- Radiation: 89Zr-Df-crefmirlimab PET scanOther: zirconium Zr 89 crefmirlimab berdoxam
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT06534190
- Locations
- 🇳🇱
VUMC, Amsterdam, Netherlands
🇪🇸Vall d'Hebron Institute of Oncology (VHIO) / Vall d'Hebron Institute Research (VHIR), Barcelona, Spain
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
- Conditions
- Muscle-invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Spanish Oncology Genito-Urinary Group
- Target Recruit Count
- 90
- Registration Number
- NCT06511648
- Locations
- 🇫🇷
CLCC Jean Perrin, Clermont-Ferrand, France
🇫🇷CLCC Léon Bérard, Lyon, France
🇫🇷Institut Mutualiste Montsouris, Paris, France
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06311578
- Locations
- 🇪🇸
Hosp Univ Vall D Hebron, Barcelona, Spain
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT06116786
- Locations
- 🇺🇸
Next Virginia, Fairfax, Virginia, United States
🇩🇪Charite Research Organisation GmbH, Berlin, Germany
🇩🇪Universitaetsklinikum Giessen und Marburg GmbH, Giessen, Germany
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT05908734
- Locations
- 🇧🇷
PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte, Brazil
🇧🇷Hospital do Cancer de Londrina, Londrina, Brazil
🇺🇸City of Hope, Duarte, California, United States
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 213
- Registration Number
- NCT05818683
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
🇺🇸Perlmutter Cancer Center at NYU Langone Brooklyn, Brooklyn, New York, United States
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1135
- Registration Number
- NCT05714202
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
🇨🇿Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia
🇰🇷Kangbuk Samsung Hospital, Seoul, Korea, Republic of
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT05242445
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
🇪🇸Hosp. Gral. Univ. Valencia, Valencia, Spain
🇵🇱PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p., Gdansk, Poland
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
- Conditions
- Prostate CancerSmall Cell Neuroendocrine CarcinomaSmall Cell Carcinoma
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 2
- Registration Number
- NCT04926181
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04919512
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Yangsan-si, Korea, Republic of
🇳🇱Ziekenhuisgroep Twente, Almelo, Netherlands
🇳🇱Haga ziekenhuis, Den Haag, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.